The Kalorama Information declares a rise of over $700 million funding for the market of stem cell technologies this 2012. The exploration of human stem cell research will expand its scope and it will continue to investigate the numerous benefits of cord blood banking as a source of revenue growth. The study on umbilical cord blood is considered as the least controversial source of stem cells but its process of collection is supported by many health experts and public organizations.
A healthcare market research expects that the funding can reach over $1 billion.